{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:17:08Z","timestamp":1790957828147,"version":"4.1.0"},"reference-count":39,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Research Program for Medicine and Health Science and Technology of Zhejiang Province","award":["2022KY585"],"award-info":[{"award-number":["2022KY585"]}]},{"name":"Research Program for Medicine and Health Science and Technology of Zhejiang Province","award":["2024KY761"],"award-info":[{"award-number":["2024KY761"]}]},{"name":"Zhejiang Pharmaceutical Association Foundation Project","award":["2020zyy22"],"award-info":[{"award-number":["2020zyy22"]}]},{"name":"Zhejiang Medical Doctors Association Foundation Project","award":["YS2022-3-009"],"award-info":[{"award-number":["YS2022-3-009"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,9,28]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Zanubrutinib is a second-generation Bruton\u2019s tyrosine kinase inhibitor that has been approved for the treatment of several B cell malignancies. The aim of this study was to evaluate adverse events (AEs) associated with zanubrutinib based on the real-world data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A disproportionality analysis was performed to identify the potential zanubrutinib-related AEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>The Food and Drug Administration AE Reporting System database from the fourth quarter of 2019 to the third quarter of 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>The results of the disproportionality analyses were presented as reported ORs (RORs). When the lower limit of the 95% CI for the ROR is greater than 1 and the number of AE reports is\u22653, it indicates that the preferred term (PT) may be a positive AE signal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 846 AE reports with zanubrutinib as the primary suspect drug were obtained, with 2826 AEs. A total of 74 positive PT signals were detected across 18 system organ classes (SOCs). The most significant signal for SOC was \u2018blood and lymphatic system disorders\u2019 (ROR=2.8, 95%\u2009CI 2.3 to 3.3), while the most significant signal for PT was \u2018haemorrhage subcutaneous\u2019 (ROR=190.8, 95%\u2009CI 128.0 to 284.5). 13 unexpected off-label AEs were also observed, such as abnormal hair texture, skin discolouration, hypernatraemia, pericardial effusion and hypersomnia. The median time to onset of AEs associated with zanubrutinib was 51 days (IQR 13\u2013192\u2009days) and was consistent with the early failure model. In comparison with zanubrutinib monotherapy, the combination of zanubrutinib and rituximab therapy was linked to a higher risk of specific AEs, including myelosuppression, pneumonia, leucopenia, thrombocytopenia, abdominal pain, anaemia, pancytopenia and respiratory failure. Furthermore, the combination of zanubrutinib and chemotherapy increased the risk of several severe AEs, such as cardiac arrest, elevated blood lactate dehydrogenase levels and pancytopenia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of the analysis provided valuable insights into the safety profile of zanubrutinib-treated patients, which was helpful for clinical monitoring and identifying potential AEs related to zanubrutinib.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-084991","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T20:00:35Z","timestamp":1729195235000},"page":"e084991","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02343120","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02343120","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jiangfeng","family":"Wang","sequence":"first","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Department of Pharmaceutical Services, Ipharmacare Ltd, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6581-2427","authenticated-orcid":false,"given":"Xiaochun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hangzhou Medical College, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4731-8410","authenticated-orcid":false,"given":"Jinlong","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Hangzhou Normal University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People\u2019s Republic of China"},{"name":"Hangzhou Normal University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Yang","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"2025101812213126000_14.10.e084991.1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton Tyrosine Kinase Inhibitors: Present and Future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J"},{"key":"2025101812213126000_14.10.e084991.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"2025101812213126000_14.10.e084991.3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease","volume":"13","author":"Von Hundelshausen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025101812213126000_14.10.e084991.4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow\u2010up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"American J Hematol"},{"key":"2025101812213126000_14.10.e084991.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"2025101812213126000_14.10.e084991.6","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"key":"2025101812213126000_14.10.e084991.7","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14561"},{"key":"2025101812213126000_14.10.e084991.8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025101812213126000_14.10.e084991.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"2025101812213126000_14.10.e084991.10","first-page":"91","article-title":"Zanubrutinib: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025101812213126000_14.10.e084991.11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41408-023-00902-x","article-title":"Zanubrutinib: past, present, and future","volume":"13","author":"Tam","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025101812213126000_14.10.e084991.12","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"key":"2025101812213126000_14.10.e084991.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"2025101812213126000_14.10.e084991.14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1130595","article-title":"Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions","volume":"13","author":"Wolska-Washer","year":"2023","journal-title":"Front Oncol"},{"key":"2025101812213126000_14.10.e084991.15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025101812213126000_14.10.e084991.16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025101812213126000_14.10.e084991.17","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv"},{"key":"2025101812213126000_14.10.e084991.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.12.011"},{"key":"2025101812213126000_14.10.e084991.19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"2025101812213126000_14.10.e084991.20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.seizure.2023.07.003","article-title":"Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system","volume":"110","author":"Liu","year":"2023","journal-title":"Seizure"},{"key":"2025101812213126000_14.10.e084991.21","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2025101812213126000_14.10.e084991.22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14740338.2023.2243220","article-title":"Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2025101812213126000_14.10.e084991.23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40164-023-00448-5","article-title":"Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies","volume":"12","author":"Song","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"2025101812213126000_14.10.e084991.24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.720704","article-title":"Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice","volume":"11","author":"O\u2019Brien","year":"2021","journal-title":"Front Oncol"},{"key":"2025101812213126000_14.10.e084991.25","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s00277-023-05371-7","article-title":"A prediction model for severe hematological toxicity of BTK inhibitors","volume":"102","author":"Jiang","year":"2023","journal-title":"Ann Hematol"},{"key":"2025101812213126000_14.10.e084991.26","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025101812213126000_14.10.e084991.27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib\u2010associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2025101812213126000_14.10.e084991.28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122955"},{"key":"2025101812213126000_14.10.e084991.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222273"},{"key":"2025101812213126000_14.10.e084991.30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton\u2019s Tyrosine Kinase: An Emerging Key Player in Innate Immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front Immunol"},{"key":"2025101812213126000_14.10.e084991.31","doi-asserted-by":"crossref","first-page":"103696","DOI":"10.1016\/j.critrevonc.2022.103696","article-title":"Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis","volume":"174","author":"Nocco","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025101812213126000_14.10.e084991.32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.995522","article-title":"Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database","volume":"13","author":"Wan","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025101812213126000_14.10.e084991.33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1473-2165.2007.00294.x","article-title":"Relaxing\/straightening of Afro-ethnic hair: historical overview","volume":"6","author":"de S\u00e1 Dias","year":"2007","journal-title":"J Cosmet Dermatol"},{"key":"2025101812213126000_14.10.e084991.34","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2016.0225","article-title":"Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia","volume":"152","author":"Bitar","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025101812213126000_14.10.e084991.35","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv"},{"key":"2025101812213126000_14.10.e084991.36","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025101812213126000_14.10.e084991.37","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1080\/10428194.2022.2074985","article-title":"A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed\/refractory aggressive and indolent B-cell lymphoma","volume":"63","author":"Zhang","year":"2022","journal-title":"Leukemia & Lymphoma"},{"key":"2025101812213126000_14.10.e084991.38","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-174465","article-title":"Zanubrutinib and Venetoclax As Initial Therapy for CLL\/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)","volume":"142","author":"Allan","year":"2023","journal-title":"Blood"},{"key":"2025101812213126000_14.10.e084991.39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1219167","article-title":"Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement","volume":"14","author":"Geng","year":"2023","journal-title":"Front Immunol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-084991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:21:40Z","timestamp":1760815300000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-084991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,17]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/bmjopen-2024-084991"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-084991","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}